| pubmed-article:18383187 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18383187 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:18383187 | lifeskim:mentions | umls-concept:C0024301 | lld:lifeskim |
| pubmed-article:18383187 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:18383187 | lifeskim:mentions | umls-concept:C1980006 | lld:lifeskim |
| pubmed-article:18383187 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18383187 | pubmed:dateCreated | 2008-10-21 | lld:pubmed |
| pubmed-article:18383187 | pubmed:abstractText | We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, the fifth described case to date. We review the literature for the potential causal relationship between RIT and secondary myelodysplastic syndromes/acute myeloid leukaemia. | lld:pubmed |
| pubmed-article:18383187 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18383187 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18383187 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18383187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18383187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18383187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18383187 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18383187 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18383187 | pubmed:issn | 0278-0232 | lld:pubmed |
| pubmed-article:18383187 | pubmed:author | pubmed-author:GalimbertiSar... | lld:pubmed |
| pubmed-article:18383187 | pubmed:author | pubmed-author:PetriniMarioM | lld:pubmed |
| pubmed-article:18383187 | pubmed:author | pubmed-author:BoniGiuseppeG | lld:pubmed |
| pubmed-article:18383187 | pubmed:author | pubmed-author:CecconiNadiaN | lld:pubmed |
| pubmed-article:18383187 | pubmed:author | pubmed-author:OrciuoloEnric... | lld:pubmed |
| pubmed-article:18383187 | pubmed:author | pubmed-author:FocosiDaniele... | lld:pubmed |
| pubmed-article:18383187 | pubmed:copyrightInfo | Copyright (c) 2008 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:18383187 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18383187 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:18383187 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18383187 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18383187 | pubmed:pagination | 179-81 | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:meshHeading | pubmed-meshheading:18383187... | lld:pubmed |
| pubmed-article:18383187 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18383187 | pubmed:articleTitle | Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma. | lld:pubmed |
| pubmed-article:18383187 | pubmed:affiliation | Division of Hematology, Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, Italy. focosi@icgeb.org | lld:pubmed |
| pubmed-article:18383187 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18383187 | pubmed:publicationType | Case Reports | lld:pubmed |
